

Neuro Oncol. 2024 Nov 13:noae239. doi: 10.1093/neuonc/noae239. Online ahead of print.

Meningiomas: Sex-Specific Differences and Prognostic Implications of a Chromosome X Loss

Natalie Berghaus^{1 2}, Thomas Hielscher³, Dilan Savran^{1 2}, Daniel Schrimpf^{1 2},
Sybren L N Maas^{4 5}, Matthias Preusser⁶, Michael Weller⁷, Till Acker⁸, Christel Herold-Mende⁹,
Wolfgang Wick^{10 11}, Andreas von Deimling^{1 2}, Felix Sahm^{1 2}

Affiliations

PMID: 39535060 DOI: [10.1093/neuonc/noae239](https://doi.org/10.1093/neuonc/noae239)

Abstract

Background: Meningiomas are the most common primary intracranial tumours in adults. Several studies proposed new stratification systems with a more accurate risk prediction than the WHO grading, e.g. based on methylation and copy number variations (CNVs). Yet, common shortcomings in these analyses are either a lack of stratification by sex of patients or excluding the gonosomes from CNV assessment.

Methods: Within this study, DNA methylation array data from 7,424 meningioma samples as well as targeted sequencing, clinical annotations and morphology subtyping of 796 samples were examined for differences between females and males regarding mutations, methylation classes, copy number variations and histology.

Results: Meningiomas from females accounted for about 53 % of the malignant tumours and present a loss of one X chromosome in 57 % of these malignant cases. In the group of benign tumours, females comprised about 75 % of the patients. Therein, a loss of one X chromosome was detected in only about 10 % of the cases but was associated with a significantly worse progression free survival.

Conclusion: Although genomic instability is a common feature of malignant meningiomas, particularly loss of the X chromosome in tumours of female patients in otherwise histologically and molecularly low-risk tumours confers higher risk. Hence, the gonosomal copy number status can be leveraged for increased diagnostic accuracy.

Keywords: Copy Number Variations; Meningioma; X chromosome.

© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

[PubMed Disclaimer](#)